| pubmed-article:1537287 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1537287 | lifeskim:mentions | umls-concept:C0023602 | lld:lifeskim |
| pubmed-article:1537287 | lifeskim:mentions | umls-concept:C0021755 | lld:lifeskim |
| pubmed-article:1537287 | lifeskim:mentions | umls-concept:C0013081 | lld:lifeskim |
| pubmed-article:1537287 | lifeskim:mentions | umls-concept:C0021665 | lld:lifeskim |
| pubmed-article:1537287 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:1537287 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1537287 | pubmed:dateCreated | 1992-4-2 | lld:pubmed |
| pubmed-article:1537287 | pubmed:abstractText | We have reported previously that insulin-like growth factor-I (IGF-I) messenger RNA (mRNA) is expressed in Leydig cells and that IGF-I can enhance androgen production, whereas interleukin-1 (IL-1) is a potent inhibitor of Leydig cell steroidogenesis. Molecular cloning studies have confirmed the existence of at least two species of IL-1: IL-1 alpha and IL-1 beta. Both IL-1 alpha and beta bind to the same receptors and have the same spectrum of biological activities. The purpose of the present study was to elucidate the molecular mechanisms of the interaction between IGF-I and IL-1 both in vivo and in vitro. Adult Sprague-Dawley rats (55-65 days old) were treated with three injections of human recombinant IL-1 beta (1 microgram/rat ip) at 12-h intervals. Rats were killed 2 h after the last injection of IL-1 beta. Purified Leydig cells were isolated and RNA extracted for Northern blot analyses. For in vitro studies, highly purified Leydig cells were cultured in Dulbecco's modified Eagle's medium/F-12 supplemented with 0.1% fetal calf serum with or without IL-1 beta (1-100 ng/ml) for 24 h. RNA was then extracted from these cells. For time course studies, purified Leydig cells were initially cultured for 24 h. Fresh medium was then added with or without IL-1 beta (10 ng/ml), and the cultures were continued for an additional 2, 4, or 6 h. In vivo administration of IL-1 beta inhibited IGF-I mRNA expression in Leydig cells (a 40% reduction, P less than 0.05). IL-1 beta also suppressed IGF-I mRNA expression in Leydig cells in vitro in a time- and dose-dependent fashion. Inhibitory effects of IL-1 beta (10 ng/ml) could be demonstrated as early as 2 h and reached a nadir at 6 h (a 60% reduction, P less than 0.05). IL-1 beta (100 ng/ml) inhibited IGF-I mRNA expression to about 10% of the controls (P less than 0.01). Moreover, the inhibitory effect of IL-1 beta could be reversed by the addition of IL-1 receptor antagonist. In conclusion, IL-1 beta could directly inhibit the mRNA expression in Leydig cells for IGF-I, an important autocrine modulator of Leydig cell function. This suggests that the effect of IL-1 beta on Leydig cell function is, at least in part, achieved by down-regulation of IGF-I mRNA levels. | lld:pubmed |
| pubmed-article:1537287 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1537287 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1537287 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1537287 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1537287 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1537287 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1537287 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1537287 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1537287 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:1537287 | pubmed:issn | 0013-7227 | lld:pubmed |
| pubmed-article:1537287 | pubmed:author | pubmed-author:WangDD | lld:pubmed |
| pubmed-article:1537287 | pubmed:author | pubmed-author:LinTT | lld:pubmed |
| pubmed-article:1537287 | pubmed:author | pubmed-author:ChangWW | lld:pubmed |
| pubmed-article:1537287 | pubmed:author | pubmed-author:NagpalM LML | lld:pubmed |
| pubmed-article:1537287 | pubmed:author | pubmed-author:CalkinsJ HJH | lld:pubmed |
| pubmed-article:1537287 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1537287 | pubmed:volume | 130 | lld:pubmed |
| pubmed-article:1537287 | pubmed:geneSymbol | IGF-I | lld:pubmed |
| pubmed-article:1537287 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1537287 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1537287 | pubmed:pagination | 1217-24 | lld:pubmed |
| pubmed-article:1537287 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:meshHeading | pubmed-meshheading:1537287-... | lld:pubmed |
| pubmed-article:1537287 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1537287 | pubmed:articleTitle | Down-regulation of Leydig cell insulin-like growth factor-I gene expression by interleukin-1. | lld:pubmed |
| pubmed-article:1537287 | pubmed:affiliation | Medical Service, W. J. B. Dorn Veterans Hospital, Columbia, South Carolina 29201. | lld:pubmed |
| pubmed-article:1537287 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1537287 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1537287 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1537287 | lld:pubmed |
